comparemela.com

Latest Breaking News On - Low risk mds - Page 1 : comparemela.com

Early Transfusions, Treatments May Improve Outcomes in Low-Risk MDS

Receiving early transfusions and treatment to reduce transfusion dependency significantly improves survival and quality of life in low-risk MDS.

Adam zayacRutgers cancer instituteJournal of the national comprehensive cancer networkRutgers robert wood johnson medical schoolRwjbarnabas healthNational comprehensive cancer networkBlood cancer drug decreases levelsEarly transfusionsRutgers robert wood johnson medicalEarly transfusionPatients with lower riskLow risk mdsEarly blood transfusions

Study Describes Characteristics, Outcomes of Patients With Low-Risk MDS

Investigators say a better understanding of risk factors and categories can help personalize care for patients living with myelodysplastic syndrome (MDS).

Moffitt cancer centerInternational prognostic scoring systemImage creditMyelodysplastic syndromesLr mdsMoffitt cancer centerHigh risk mdsLow risk mds

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsData fromMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsData fromMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

vimarsana © 2020. All Rights Reserved.